Tevogen Inc. has put a possible acquisition on the table, signing a letter of intent to explore buying HRK Healthcare LLC. The company is looking to move beyond its biotech and AI roots, eyeing a future as a fully integrated healthcare operator with real revenue streams.
Tevogen trades on Nasdaq as TVGN. The letter of intent landed on October 8, 2026, with syndication following the same week. The company wants to pull together its biopharma arm, Tevogen Bio, and its tech unit, Tevogen.AI, with a new healthcare services segment. If the HRK deal goes through, Tevogen could start offering management services and widen its reach.
No independent data is available on HRK Healthcare LLC's revenue, client base, licensing, ownership, or prior transactions, making it impossible to assess the strategic or financial value of the potential acquisition based on confirmed information.
Deal structure and strategic intent
The letter of intent is both non-exclusive and non-binding. That means talks are early, and nothing is locked in. Any deal will need due diligence, a final contract, regulatory sign-off, and standard closing steps. Tevogen is also looking at other possible moves in life sciences and healthcare, but there is no certainty that any deal—including this one—will close.
Dr. Manmohan Patel, MD, Tevogen’s lead investor, called out the HRK opportunity as a way to grow the company’s healthcare services and push its goal of making life-saving medicines more affordable and accessible. He said, “The potential HRK transaction represents an opportunity to expand the Company’s healthcare services capabilities and advance its mission of improving the affordability and accessibility of life-saving medicines. If consummated, this opportunity, together with other strategic acquisition initiatives, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue.”
Integrated model and market context
Tevogen wants to blend biotech, AI, and healthcare services into one operation. The company says it aims to cut the cost of critical medicines and reach more patients by using science and efficient operations. This approach tracks with recent industry moves, like the Novartis-Abogen deal, where scale and integration are seen as keys to competing.
Tevogen’s announcement spells out the risks. The company points to the chance the deal may fall through, regulatory hurdles, shifting markets, and the challenge of pulling off growth plans. These aren’t just legal disclaimers. Healthcare M&A is volatile, especially for companies trying to combine biopharma and AI with services.
The approximately $100 million annual revenue figure cited by Tevogen refers to a potential combined result from several strategic acquisitions, not to confirmed revenue from HRK Healthcare LLC or a guaranteed financial forecast.
Tevogen is willing to chase big acquisitions but doesn’t gloss over the obstacles. The company’s plan is ambitious, but its public statements show a clear-eyed view of sector risks. Execution and integration will decide whether Tevogen can deliver value across its business lines.
No independent confirmation has surfaced on a final agreement, regulatory green light, or deal closing. The price, payment terms, and share of business on offer remain undisclosed. The letter of intent is still just a first step. Public filings and newswires show no separate coverage from Reuters, Bloomberg, AP, the SEC, or government regulators, and HRK Healthcare has not issued any public comment.
